Rodman & Renshaw initiated coverage of Passage Bio with a Buy rating and $7 price target.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PASG:
- Passage Bio to Present at H.C. Wainwright 26th Annual Global Investment Conference
- Passage Bio Presents Updated Corporate Insights
- Passage Bio reports Q2 EPS (26c), consensus (31c)
- Passage Bio Reports Second Quarter 2024 Financial Results and Provides Recent Business Highlights
- Passage Bio Executive Reshuffle and Strategic Focus Shift